$131.69
-0.01000-0.01%
Pre-Market: 4:35 AM EDT
Comments
Loading...
Intra-Cellular Therapies Insider Trading Activity | NASDAQ:ITCI | Benzinga
Track the latest Intra-Cellular Therapies insider trading activity. Stay informed on recent buys, sells, and market impact for Intra-Cellular Therapies stock.
What is Insider Activity?
Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide valuable insights into their confidence in the company's future performance.
What are Intra-Cellular Therapies Inc Insiders Doing?
Insiders have report no purchases/sales in the last 30 days.
Notable Recent Insider Buys and Sales
There has been no Insider buying or selling in the last 90 days.
Ownership Statistics for Intra-Cellular Therapies Inc
Shares Outstanding
106.522M
Insider Shares Owned
2.208M
Insider Percentage Owned
2.08%
Institutional Shares Held
53.232M
Institutional Percentage Held
50.1%
| Dec 06, 2024 | Sharon Mates | CHAIRMAN AND CEO | 0.00 | $48.83 | -$7.42M | SELL-OPTIONS | 0.00% | 1.07M | Dec 04 - Dec 05 | View |
| Nov 14, 2024 | Michael Halstead | PRESIDENT | 0.00 | $59.28 | -$2.45M | SELL-OPTIONS | 0.00% | 0.00 | Nov 12 - Nov 13 | View |
| Aug 30, 2024 | Sharon Mates | CHAIRMAN AND CEO | 0.00 | $42.72 | -$4.20M | SELL-OPTIONS | 0.00% | 1.07M | Aug 29 - Aug 30 | View |
| Aug 28, 2024 | Sharon Mates | CHAIRMAN AND CEO | 0.00 | $45.55 | -$5.37M | SELL-OPTIONS | 0.00% | 1.07M | Aug 26 - Aug 28 | View |
| Aug 23, 2024 | Sharon Mates | CHAIRMAN AND CEO | 0.00 | $46.31 | -$6.96M | SELL-OPTIONS | 0.00% | 1.07M | Aug 21 - Aug 23 | View |
| Aug 20, 2024 | Mark Neumann | EVP, CHIEF COMMERCIAL OFFICER | 0.00 | $55.98 | -$714.69K | SELL-OPTIONS | 0.00% | 29.70K | Aug 16 | View |
| Jun 25, 2024 | RORY RIGGS | — | 17.11K | $46.21 | $6.66 | SELL-OPTIONS | 17.19% | 116.60K | Jun 23 - Jun 24 | View |
| Jun 21, 2024 | ROBERT NOSTRAND VAN | — | 0.00 | $46.38 | -$1.18M | SELL-OPTIONS | 0.00% | 9.69K | Jun 18 | View |
| Mar 11, 2024 | Sharon Mates | CHAIRMAN, PRESIDENT & CEO | -40.71K | $66.07 | -$4.05M | SELL | -3.73% | 1.05M | Mar 07 - Mar 11 | View |
| Mar 11, 2024 | Lawrence J Hineline | SVP FINANCE, CFO | -13.13K | $61.53 | -$1.28M | SELL | -100.00% | 0.00 | Mar 07 - Mar 11 | View |
| Mar 11, 2024 | Michael Halstead | EVP AND GENERAL COUNSEL | -13.13K | $66.09 | -$1.35M | SELL | -100.00% | 0.00 | Mar 07 - Mar 11 | View |
| Mar 11, 2024 | Mark Neumann | EVP, CHIEF COMMERCIAL OFFICER | -13.13K | $66.23 | -$1.36M | SELL | -30.66% | 29.70K | Mar 07 - Mar 11 | View |
| Mar 11, 2024 | Suresh Durgam | EVP, CHIEF MEDICAL OFFICER | -2.82K | $66.21 | -$672.79K | SELL | -12.45% | 19.80K | Mar 07 - Mar 11 | View |
| Feb 28, 2024 | ROBERT NOSTRAND VAN | — | 0.00 | $45.75 | -$1.09M | SELL-OPTIONS | 0.00% | 9.61K | Feb 27 | View |
| Feb 27, 2024 | Michael Halstead | EVP AND GENERAL COUNSEL | 0.00 | $69.53 | -$549.78K | SELL-OPTIONS | 0.00% | 0.00 | Feb 23 - Feb 26 | View |
| Feb 27, 2024 | Lawrence J Hineline | SVP FINANCE, CFO | 0.00 | $53.16 | -$708.97K | SELL-OPTIONS | 0.00% | 0.00 | Feb 23 - Feb 26 | View |
| Feb 27, 2024 | Sharon Mates | CHAIRMAN, PRESIDENT & CEO | 0.00 | $69.79 | -$1.58M | SELL-OPTIONS | 0.00% | 1.05M | Feb 23 - Feb 26 | View |
| Feb 27, 2024 | Suresh Durgam | EVP, CHIEF MEDICAL OFFICER | 3.79K | $70.17 | -$288.53K | SELL-OPTIONS | 66.66% | 9.49K | Feb 23 - Feb 26 | View |
| Feb 27, 2024 | Mark Neumann | EVP, CHIEF COMMERCIAL OFFICER | 0.00 | $70.13 | -$554.49K | SELL-OPTIONS | 0.00% | 29.70K | Feb 23 - Feb 26 | View |
| Feb 27, 2024 | JOEL MARCUS | — | 10.43K | $58.81 | -$9.58K | SELL-OPTIONS | 26.58% | 49.66K | Feb 26 | View |
| Feb 05, 2024 | Michael Halstead | EVP AND GENERAL COUNSEL | 0.00 | $66.42 | -$787.72K | GRANT | 0.00% | 0.00 | Feb 01 - Feb 02 | View |
| Feb 05, 2024 | Sharon Mates | CHAIRMAN, PRESIDENT & CEO | 0.00 | $67.07 | -$2.27M | GRANT | 0.00% | 1.05M | Feb 01 - Feb 02 | View |
| Feb 05, 2024 | Mark Neumann | EVP, CHIEF COMMERCIAL OFFICER | 0.00 | $67.15 | -$796.37K | GRANT | 0.00% | 29.70K | Feb 01 - Feb 02 | View |
| Feb 05, 2024 | Lawrence J Hineline | SVP FINANCE, CFO | 0.00 | $66.62 | -$745.04K | GRANT | 0.00% | 0.00 | Feb 01 - Feb 02 | View |
| Feb 05, 2024 | Suresh Durgam | EVP, CHIEF MEDICAL OFFICER | 5.69K | $67.19 | -$414.35K | GRANT | ∞ | 5.69K | Feb 01 - Feb 02 | View |
| Jan 18, 2024 | Sharon Mates | CHAIRMAN, PRESIDENT & CEO | 0.00 | $41.56 | -$9.45M | SELL-OPTIONS | 0.00% | 1.05M | Jan 16 - Jan 18 | View |
| Jan 12, 2024 | Michael Halstead | EVP AND GENERAL COUNSEL | 0.00 | $40.22 | -$2.66M | SELL-OPTIONS | 0.00% | 0.00 | Jan 11 | View |
| Jan 04, 2024 | Suresh Durgam | EVP, CHIEF MEDICAL OFFICER | 0.00 | $45.24 | -$3.16M | SELL-OPTIONS | 0.00% | 0.00 | Jan 02 | View |
| Dec 15, 2023 | Suresh Durgam | EVP, CHIEF MEDICAL OFFICER | -21.26K | $65.00 | -$1.38M | SELL | -100.00% | 0.00 | Dec 13 | View |
| Nov 14, 2023 | Michael Halstead | EVP AND GENERAL COUNSEL | 0.00 | $33.73 | -$2.02M | SELL-OPTIONS | 0.00% | 0.00 | Nov 13 | View |
| Nov 08, 2023 | Mark Neumann | EVP, CHIEF COMMERCIAL OFFICER | -15.64K | $39.78 | -$1.72M | SELL | -34.49% | 29.70K | Nov 06 | View |
| Sep 19, 2023 | Sharon Mates | CHAIRMAN, PRESIDENT & CEO | -100.00K | $53.94 | -$5.39M | SELL | -8.69% | 1.05M | Sep 18 - Sep 19 | View |
| Aug 09, 2023 | Mark Neumann | EVP, CHIEF COMMERCIAL OFFICER | 0.00 | $38.69 | -$2.22M | SELL-OPTIONS | 0.00% | 45.34K | Aug 07 | View |
| Jul 20, 2023 | Suresh Durgam | EVP, CHIEF MEDICAL OFFICER | -1.84K | $65.00 | -$119.73K | SELL | -7.97% | 21.26K | Jul 17 | View |
| Jun 16, 2023 | Lawrence J Hineline | SVP FINANCE CFO | 0.00 | $53.14 | -$1.77M | SELL-OPTIONS | 0.00% | 0.00 | Jun 14 | View |
| Apr 19, 2023 | ROBERT NOSTRAND VAN | DIRECTOR | 0.00 | $38.02 | -$499.50K | SELL-OPTIONS | 0.00% | 9.35K | Apr 17 | View |
| Mar 30, 2023 | Mark Neumann | EVP, CHIEF COMMERCIAL OFFICER | -15.60K | $54.31 | -$847.38K | SELL | -25.60% | 45.34K | Mar 28 | View |
| Mar 13, 2023 | Suresh Durgam | EVP, CHIEF MEDICAL OFFICER | 0.00 | $45.04 | -$330.79K | SELL-OPTIONS | 0.00% | 23.10K | Mar 10 - Mar 13 | View |
| Mar 13, 2023 | Mark Neumann | EVP, CHIEF COMMERCIAL OFFICER | 11.74K | $43.84 | -$539.60K | SELL-OPTIONS | 23.87% | 60.94K | Mar 09 - Mar 13 | View |
| Mar 13, 2023 | Michael Halstead | EVP AND GENERAL COUNSEL | 0.00 | $43.66 | -$1.05M | SELL-OPTIONS | 0.00% | 0.00 | Mar 09 - Mar 13 | View |
| Mar 13, 2023 | Lawrence J Hineline | SVP FINANCE CFO | 0.00 | $43.55 | -$925.23K | SELL-OPTIONS | 0.00% | 0.00 | Mar 09 - Mar 13 | View |
| Mar 13, 2023 | Sharon Mates | CHAIRMAN, PRESIDENT & CEO | 20.00K | $23.51 | -$2.66M | SELL-OPTIONS | 1.77% | 1.15M | Mar 09 - Mar 13 | View |
| Mar 03, 2023 | Mark Neumann | EVP, CHIEF COMMERCIAL OFFICER | -7.24K | $50.01 | -$362.12K | SELL | -12.83% | 49.20K | Mar 01 | View |
| Feb 27, 2023 | Mark Neumann | EVP, CHIEF COMMERCIAL OFFICER | 3.86K | $47.12 | -$190.65K | SELL-OPTIONS | 7.34% | 56.44K | Feb 23 - Feb 24 | View |
| Feb 27, 2023 | Suresh Durgam | SVP, CHIEF MEDICAL OFFICER | 0.00 | $47.14 | -$372.69K | SELL-OPTIONS | 0.00% | 23.10K | Feb 23 - Feb 24 | View |
| Feb 27, 2023 | Michael Halstead | EVP AND GENERAL COUNSEL | 0.00 | $47.03 | -$371.82K | SELL-OPTIONS | 0.00% | 0.00 | Feb 23 - Feb 24 | View |
| Feb 27, 2023 | Lawrence J Hineline | SVP FINANCE CFO | 0.00 | $47.03 | -$350.61K | SELL-OPTIONS | 0.00% | 0.00 | Feb 23 - Feb 24 | View |
| Feb 27, 2023 | Sharon Mates | CHAIRMAN, PRESIDENT & CEO | 30.00K | $25.14 | -$964.61K | SELL-OPTIONS | 2.73% | 1.13M | Feb 23 - Feb 24 | View |
| Feb 22, 2023 | Mark Neumann | EVP, CHIEF COMMERCIAL OFFICER | 7.24K | $47.01 | -$183.25K | SELL-OPTIONS | 15.97% | 52.58K | Feb 18 - Feb 21 | View |
| Feb 22, 2023 | Suresh Durgam | SVP, CHIEF MEDICAL OFFICER | 0.00 | $46.84 | -$391.30K | SELL-OPTIONS | 0.00% | 23.10K | Feb 18 - Feb 21 | View |
| Feb 22, 2023 | Michael Halstead | EVP AND GENERAL COUNSEL | 0.00 | $46.84 | -$521.70K | SELL-OPTIONS | 0.00% | 0.00 | Feb 18 - Feb 21 | View |
| Feb 22, 2023 | Lawrence J Hineline | SVP FINANCE CFO | 0.00 | $31.04 | -$2.49M | SELL-OPTIONS | 0.00% | 0.00 | Feb 17 - Feb 21 | View |
| Feb 22, 2023 | Sharon Mates | CHAIRMAN, PRESIDENT & CEO | 0.00 | $46.83 | -$1.30M | SELL-OPTIONS | 0.00% | 1.10M | Feb 18 - Feb 21 | View |
| Dec 21, 2022 | JOEL MARCUS | DIRECTOR | -5.00K | $50.82 | -$254.10K | SELL | -11.30% | 39.23K | Dec 19 | View |
| Dec 15, 2022 | Sharon Mates | CHAIRMAN, PRESIDENT & CEO | -33.08K | $55.00 | -$1.82M | SELL | -2.92% | 1.10M | Dec 13 | View |
| Dec 02, 2022 | Michael Halstead | EVP AND GENERAL COUNSEL | 0.00 | $34.60 | -$1.91M | SELL-OPTIONS | 0.00% | 0.00 | Dec 01 | View |
| Nov 08, 2022 | JOEL MARCUS | DIRECTOR | -10.00K | $52.30 | -$523.02K | SELL | -18.44% | 44.23K | Nov 07 | View |
| Sep 23, 2022 | Lawrence J Hineline | SVP FINANCE CFO | 0.00 | $30.55 | -$1.97M | SELL-OPTIONS | 0.00% | 0.00 | Sep 21 | View |
| Aug 12, 2022 | ROBERT NOSTRAND VAN | DIRECTOR | 0.00 | $34.89 | -$1.33M | SELL-OPTIONS | 0.00% | 9.04K | Aug 11 | View |
| Aug 12, 2022 | JOEL MARCUS | DIRECTOR | -10.00K | $59.22 | -$592.20K | SELL | -15.57% | 54.23K | Aug 11 | View |
| May 13, 2022 | JOEL MARCUS | DIRECTOR | 4.19K | $55.00 | -$550.00K | SELL-OPTIONS | 6.98% | 64.23K | Jun 18 - May 12 | View |
| Apr 08, 2022 | Mark Neumann | EVP, CHIEF COMMERCIAL OFFICER | 0.00 | $38.55 | -$4.46M | SELL-OPTIONS | 0.00% | 45.34K | Apr 08 | View |
| Mar 18, 2022 | RORY RIGGS | DIRECTOR | -226.67K | $60.10 | -$13.62M | SELL | -74.69% | 76.81K | Mar 16 - Mar 18 | View |
| Mar 09, 2022 | JOEL MARCUS | DIRECTOR | -20.00K | $53.14 | -$1.06M | SELL | -26.35% | 55.90K | Mar 07 - Mar 08 | View |
| Mar 04, 2022 | Suresh Durgam | CHIEF MEDICAL OFFICER | -8.04K | $56.28 | -$452.31K | SELL | -25.81% | 23.10K | Mar 02 - Mar 04 | View |
| Feb 25, 2022 | Suresh Durgam | CHIEF MEDICAL OFFICER | 3.86K | $52.27 | -$211.47K | SELL-OPTIONS | 14.15% | 31.14K | Feb 23 - Feb 24 | View |
| Feb 25, 2022 | Mark Neumann | EVP, CHIEF COMMERCIAL OFFICER | 0.00 | $52.21 | -$412.81K | SELL-OPTIONS | 0.00% | 45.34K | Feb 23 - Feb 24 | View |
| Feb 25, 2022 | Michael Halstead | EVP AND GENERAL COUNSEL | 0.00 | $51.98 | -$410.93K | SELL-OPTIONS | 0.00% | 0.00 | Feb 23 - Feb 24 | View |
| Feb 25, 2022 | Lawrence J Hineline | SVP FINANCE CFO | 0.00 | $51.97 | -$387.35K | SELL-OPTIONS | 0.00% | 0.00 | Feb 23 - Feb 24 | View |
| Feb 25, 2022 | Sharon Mates | CHAIRMAN, PRESIDENT & CEO | 0.00 | $51.98 | -$1.17M | SELL-OPTIONS | 0.00% | 1.09M | Feb 23 - Feb 24 | View |
| Feb 23, 2022 | Suresh Durgam | CHIEF MEDICAL OFFICER | 4.18K | $55.29 | -$230.96K | SELL-OPTIONS | 18.08% | 27.28K | Feb 18 - Feb 22 | View |
| Feb 23, 2022 | Mark Neumann | EVP, CHIEF COMMERCIAL OFFICER | 0.00 | $55.29 | -$615.83K | SELL-OPTIONS | 0.00% | 45.34K | Feb 18 - Feb 22 | View |
| Feb 23, 2022 | Michael Halstead | EVP AND GENERAL COUNSEL | 0.00 | $55.40 | -$617.10K | SELL-OPTIONS | 0.00% | 0.00 | Feb 18 - Feb 22 | View |
| Feb 23, 2022 | Lawrence J Hineline | SVP FINANCE CFO | 0.00 | $55.40 | -$578.51K | SELL-OPTIONS | 0.00% | 0.00 | Feb 18 - Feb 22 | View |
| Feb 23, 2022 | Sharon Mates | CHAIRMAN, PRESIDENT & CEO | 0.00 | $55.39 | -$1.54M | SELL-OPTIONS | 0.00% | 1.09M | Feb 18 - Feb 22 | View |
| Jan 20, 2022 | Suresh Durgam | CHIEF MEDICAL OFFICER | -6.22K | $42.03 | -$261.55K | SELL | -21.22% | 23.10K | Jan 18 | View |
| Jan 11, 2022 | Suresh Durgam | CHIEF MEDICAL OFFICER | 6.22K | $40.76 | -$280.02K | SELL-OPTIONS | 26.93% | 29.33K | Jan 08 - Jan 10 | View |
| Jan 11, 2022 | Mark Neumann | EVP, CHIEF COMMERCIAL OFFICER | 0.00 | $40.78 | -$854.25K | SELL-OPTIONS | 0.00% | 45.34K | Jan 08 - Jan 10 | View |
| Jan 11, 2022 | Michael Halstead | EVP AND GENERAL COUNSEL | 0.00 | $40.77 | -$800.77K | SELL-OPTIONS | 0.00% | 0.00 | Jan 08 - Jan 10 | View |
| Jan 11, 2022 | Lawrence J Hineline | SVP FINANCE CFO | 0.00 | $40.76 | -$800.42K | SELL-OPTIONS | 0.00% | 0.00 | Jan 08 - Jan 10 | View |
| Jan 11, 2022 | Sharon Mates | CHAIRMAN, PRESIDENT & CEO | 0.00 | $40.78 | -$1.71M | SELL-OPTIONS | 0.00% | 1.09M | Jan 08 - Jan 10 | View |
| Dec 23, 2021 | Michael Halstead | EVP AND GENERAL COUNSEL | 0.00 | $31.97 | -$5.51M | SELL-OPTIONS | 0.00% | 0.00 | Dec 21 | View |
| Dec 23, 2021 | Lawrence J Hineline | SVP FINANCE CFO | 0.00 | $32.20 | -$5.39M | SELL-OPTIONS | 0.00% | 0.00 | Dec 21 | View |
| Oct 19, 2021 | Mark Neumann | EVP, CHIEF COMMERCIAL OFFICER | 0.00 | $40.86 | -$549.55K | SELL-OPTIONS | 0.00% | 45.34K | Oct 15 - Oct 18 | View |
| Oct 18, 2021 | Sharon Mates | CHAIRMAN, PRESIDENT & CEO | -48.92K | $21.42 | -$2.00M | SELL | -4.28% | 1.09M | Oct 14 - Oct 18 | View |
| Jun 15, 2021 | JOEL MARCUS | DIRECTOR | 1.71K | $40.31 | -$6.08K | SELL-OPTIONS | 0.14% | 1.21M | Jun 14 | View |
| May 28, 2021 | Christopher Alafi | DIRECTOR | -47.33K | $40.10 | -$1.90M | SELL | -7.32% | 598.75K | May 27 - May 28 | View |
| May 25, 2021 | Christopher Alafi | DIRECTOR | -27.68K | $40.45 | -$1.12M | SELL | -4.11% | 646.08K | May 21 - May 24 | View |
| Mar 04, 2021 | JOEL MARCUS | DIRECTOR | 4.75K | $30.75 | -$1.08K | SELL-OPTIONS | 0.39% | 1.24M | Mar 02 | View |
| Feb 22, 2021 | Suresh Durgam | CHIEF MEDICAL OFFICER | 5.62K | $39.25 | -$107.31K | SELL-OPTIONS | 32.14% | 23.10K | Feb 18 - Feb 19 | View |
| Feb 22, 2021 | Mark Neumann | EVP, CHIEF COMMERCIAL OFFICER | 5.96K | $39.22 | -$203.31K | SELL-OPTIONS | 15.12% | 45.34K | Feb 18 - Feb 19 | View |
| Feb 22, 2021 | Lawrence J Hineline | SVP FINANCE CFO | 0.00 | $39.23 | -$409.63K | SELL-OPTIONS | 0.00% | 0.00 | Feb 18 - Feb 19 | View |
| Feb 22, 2021 | Michael Halstead | EVP AND GENERAL COUNSEL | 0.00 | $39.24 | -$437.13K | SELL-OPTIONS | 0.00% | 0.00 | Feb 18 - Feb 19 | View |
| Feb 22, 2021 | Sharon Mates | CHAIRMAN, PRESIDENT & CEO | 0.00 | $39.23 | -$1.09M | SELL-OPTIONS | 0.00% | 1.13M | Feb 18 - Feb 19 | View |
| Jan 12, 2021 | Suresh Durgam | CHIEF MEDICAL OFFICER | 8.72K | $32.12 | -$140.26K | SELL-OPTIONS | 99.61% | 17.48K | Jan 08 - Jan 11 | View |
| Jan 12, 2021 | Mark Neumann | EVP, CHIEF COMMERCIAL OFFICER | 11.26K | $32.02 | -$310.08K | SELL-OPTIONS | 40.06% | 39.38K | Jan 08 - Jan 11 | View |
| Jan 12, 2021 | Lawrence J Hineline | SVP FINANCE CFO | -350.00 | $32.02 | -$628.77K | SELL | -100.00% | 0.00 | Jan 08 - Jan 11 | View |
| Jan 12, 2021 | Michael Halstead | EVP AND GENERAL COUNSEL | 0.00 | $32.03 | -$628.98K | SELL-OPTIONS | 0.00% | 0.00 | Jan 08 - Jan 11 | View |
| Jan 12, 2021 | Sharon Mates | CHAIRMAN, PRESIDENT & CEO | 0.00 | $32.01 | -$1.34M | SELL-OPTIONS | 0.00% | 1.13M | Jan 08 - Jan 11 | View |
| Jan 05, 2021 | Lawrence J Hineline | SVP FINANCE CFO | 350.00 | $31.31 | -$495.01K | SELL-OPTIONS | ∞ | 350.00 | Jan 03 - Jan 04 | View |
| Jan 05, 2021 | Michael Halstead | EVP AND GENERAL COUNSEL | 0.00 | $31.30 | -$505.83K | SELL-OPTIONS | 0.00% | 0.00 | Jan 03 - Jan 04 | View |
| Jan 05, 2021 | Sharon Mates | CHAIRMAN, PRESIDENT & CEO | -14.00K | $31.30 | -$1.51M | SELL | -1.22% | 1.13M | Jan 03 - Jan 04 | View |
| Nov 19, 2020 | Michael Halstead | — | -4.42K | $20.74 | -$1.15M | OPTION EXERCISE | -100.00% | 0.00 | Nov 17 | View |
| Nov 13, 2020 | Lawrence J Hineline | — | -8.03K | $14.23 | -$651.34K | OPTION EXERCISE | -100.00% | 0.00 | Nov 11 | View |
| Nov 12, 2020 | Sharon Mates | CHAIRMAN, PRESIDENT & CEO | -50.00K | $26.34 | -$1.32M | SELL | -4.30% | 1.11M | Nov 10 | View |
| Nov 06, 2020 | Sharon Mates | — | -50.00K | $25.00 | -$1.25M | SELL | -4.12% | 1.16M | Nov 04 | View |
| Oct 16, 2020 | Mark Neumann | — | 6.66K | $26.80 | -$182.03K | OPTION EXERCISE | 31.01% | 28.12K | Oct 15 - Oct 16 | View |
| Sep 14, 2020 | Christopher Alafi | — | 49.50K | $29.60 | $1.47M | PURCHASE | 1.02% | 4.91M | Sep 14 | View |
| Sep 11, 2020 | Lawrence J Hineline | — | -15.00K | $21.94 | -$963.86K | OPTION EXERCISE | -65.12% | 8.03K | Sep 09 | View |
| Sep 11, 2020 | Christopher Alafi | — | 21.00K | $28.08 | $589.68K | PURCHASE | 0.43% | 4.86M | Sep 11 | View |
| May 15, 2020 | JOEL MARCUS | — | -9.60K | $20.04 | -$192.42K | SELL | -0.79% | 1.20M | May 14 | View |
| May 13, 2020 | JOEL MARCUS | — | -57.30K | $20.04 | -$1.15M | SELL | -4.51% | 1.21M | May 11 - May 13 | View |
| May 13, 2020 | RICHARD LERNER | — | 21.50K | $11.62 | -$3.25K | OPTION EXERCISE | 25.67% | 105.24K | May 11 | View |
FAQ
Is insider trading legal?
Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.
What are some examples of market manipulation?
Insider trading, pump and dump schemes, front running and wash trades are all examples of market manipulation. Investors who track insider asset movement should think carefully about why these insiders are trading their stocks before moving forward.
Browse insider trades on all stocks.